About: High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Vysoce dávkovaná chemoterapie následovaná autologní transplantací kostní dřeně v 1. kompletní remisi zlepšila přežití pacientů s prognosticky nepříznivým difuzním velkobuněčným B-lymfomem.Retrospektivně jsme hodnotili výsledky léčby vysoce dávkovanou chemoterapií následovanou autologní transplantací kostní dřeně u 55 pacientů. Výsledky ukazují, že tato strategie je efektivní možností léčby pacientů mladších 65 let s nepříznivým difuzním velkobuněčným B lymfomem v kompletní nebo parciální remisí, dokonce i v éře R-chemoterapie. (cs)
  • Improved survival has been observed in poor-risk diffuse large B-cell lymphoma (DLBCL) patients treated with high-dose therapy /HDT) followed by autologous stem cell transplantation (ASCT) in firts complete remission. Reprospective studies hase suggested that HDT with ASCT can improve survival also in partial responders but some doubt about the advantage of intensive therapy in such patients still remain. We evaluated retrospectively the results of hDT and ASCT in 55 patients with confirmed DLBCL treated between may 1999 and July 2006. Thirty-six patients (65%) showed partial remission (PR) and 19 patients (35%) reached complete remission (CR) after induction treatment with (44%) or without (56%) concomitant ritusimab (R) immunotherapy. After HDT a ASCT, 69% of patients fulfilled the criteria of CR, 22 % had unconfirmed CR (CRu), 7%remained in PR and 1 patient (2%) relapsed. Twenty patients in PR after the induction treatment reached CR after ASCT, 12 other PR patients achieved CRu. The 5-year event-f
  • Improved survival has been observed in poor-risk diffuse large B-cell lymphoma (DLBCL) patients treated with high-dose therapy /HDT) followed by autologous stem cell transplantation (ASCT) in firts complete remission. Reprospective studies hase suggested that HDT with ASCT can improve survival also in partial responders but some doubt about the advantage of intensive therapy in such patients still remain. We evaluated retrospectively the results of hDT and ASCT in 55 patients with confirmed DLBCL treated between may 1999 and July 2006. Thirty-six patients (65%) showed partial remission (PR) and 19 patients (35%) reached complete remission (CR) after induction treatment with (44%) or without (56%) concomitant ritusimab (R) immunotherapy. After HDT a ASCT, 69% of patients fulfilled the criteria of CR, 22 % had unconfirmed CR (CRu), 7%remained in PR and 1 patient (2%) relapsed. Twenty patients in PR after the induction treatment reached CR after ASCT, 12 other PR patients achieved CRu. The 5-year event-f (en)
Title
  • High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission
  • High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission (en)
  • Vysoce dávkovaná terapie a autologní transplantace u pacientů s difuzním velkobuněčným B lymfomem v 1. kompletní nebo parciální remisi (cs)
skos:prefLabel
  • High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission
  • High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission (en)
  • Vysoce dávkovaná terapie a autologní transplantace u pacientů s difuzním velkobuněčným B lymfomem v 1. kompletní nebo parciální remisi (cs)
skos:notation
  • RIV/61989592:15110/08:00007645!RIV09-MSM-15110___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • Z(MSM6198959205)
http://linked.open...iv/cisloPeriodika
  • 3
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 370095
http://linked.open...ai/riv/idVysledku
  • RIV/61989592:15110/08:00007645
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • diffuse large B-cell lymphoma; autologous transplantation; rituximab; survival (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • SK - Slovenská republika
http://linked.open...ontrolniKodProRIV
  • [96FCE4FF258A]
http://linked.open...i/riv/nazevZdroje
  • Neoplasma
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 55
http://linked.open...iv/tvurceVysledku
  • Dušek, Ladislav
  • Faber, Edgar
  • Jarkovský, J.
  • Jarošová, Marie
  • Kubová, Zuzana
  • Neoral, Čestmír
  • Raida, Luděk
  • Skoumalová, Ivana
  • Vondráková, Jana
  • Procházka, Vít
  • Kučerová, Ladislava
  • Papajík, Tomáš
  • Tichý, Martin
  • Mysliveček, Miroslav
  • Pauček, Boris
  • Oral, Ivo
http://linked.open...n/vavai/riv/zamer
issn
  • 0028-2685
number of pages
http://localhost/t...ganizacniJednotka
  • 15110
is http://linked.open...avai/riv/vysledek of
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software